Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.
Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. Buti S, et al. Among authors: naglieri e. World J Clin Oncol. 2021 Nov 24;12(11):1037-1046. doi: 10.5306/wjco.v12.i11.1037. World J Clin Oncol. 2021. PMID: 34909398 Free PMC article.
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. De Placido S, et al. Among authors: naglieri e. J Clin Oncol. 2004 Jul 1;22(13):2635-42. doi: 10.1200/JCO.2004.09.088. J Clin Oncol. 2004. PMID: 15226331 Clinical Trial.
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Galliano M, Testore F, Porta C, Maglie M, Dall'agata M, Fumagalli L, Ridolfi R. Ridolfi L, et al. Among authors: naglieri e. Int J Oncol. 2011 Oct;39(4):1011-7. doi: 10.3892/ijo.2011.1099. Epub 2011 Jun 24. Int J Oncol. 2011. PMID: 21720704 Clinical Trial.
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.
D'Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Naglieri E, Galli L, Cartenì G, De Giorgi U, Pignata S, Facchini G, Rossetti S. D'Aniello C, et al. Among authors: naglieri e. Front Pharmacol. 2016 Sep 28;7:331. doi: 10.3389/fphar.2016.00331. eCollection 2016. Front Pharmacol. 2016. PMID: 27733829 Free PMC article.
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C. Facchini G, et al. Among authors: naglieri e. J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4. J Transl Med. 2019. PMID: 31464635 Free PMC article.
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
Procopio G, Chiuri VE, Giordano M, Mantini G, Maisano R, Bordonaro R, Calvani N, Facchini G, De Placido S, Airoldi M, Sbrana A, Gasparro D, Ludovico GM, Guglielmini P, Naglieri E, Fagnani D, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D. Procopio G, et al. Among authors: naglieri e. Ther Adv Med Oncol. 2020 Oct 29;12:1758835920968725. doi: 10.1177/1758835920968725. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33193831 Free PMC article.
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Santini D, et al. Among authors: naglieri e. Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791. Am J Clin Oncol. 2021. PMID: 33617179
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nolè F, Astolfi C, Sternberg CN. Fornarini G, et al. Among authors: naglieri e. ESMO Open. 2021 Jun;6(3):100118. doi: 10.1016/j.esmoop.2021.100118. Epub 2021 May 10. ESMO Open. 2021. PMID: 33984678 Free PMC article.
47 results